New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Go back to New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
(NYSE: TAK) Delayed: 20.36 +0.43 (2.16%)
Previous Close $19.93    52 Week High $0.55 
Open $20.18    52 Week Low $0.55 
Day High $20.39    P/E N/A 
Day Low $20.08    EPS $-0.20 
Volume 3,461,936